Andra AP fonden Lowers Holdings in Eli Lilly and Company $LLY

Key Points

• Andra AP fonden reduced its Eli Lilly position by 10.8% in the second quarter, selling 13,720 shares and retaining 113,513 shares worth approximately $136.2 million. Institutional investors still own 82.53% of the company.
• Eli Lilly insiders sold 13,500 shares worth about $16.0 million over the past 90 days, though both reported executive sales were made under pre-arranged Rule 10b5-1 trading plans.
• Lilly reported strong quarterly results, with revenue up 47.7% year over year and EPS of $8.38 versus the $6.40 consensus estimate. Analysts maintain a broadly bullish outlook, with a “Moderate Buy” consensus and a $1,305.25 average price target, while rising obesity-drug competition remains a key risk.

Andra AP fonden trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 113,513 shares of the company's stock after selling 13,720 shares during the quarter. Eli Lilly and Company comprises about 1.5% of Andra AP fonden's holdings, making the stock its 11th biggest holding. Andra AP fonden's holdings in Eli Lilly and Company were worth $136,151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Osbon Capital Management LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP lifted its holdings in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $39,000. Finally, Aventus Investment Advisors Inc. boosted its position in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock valued at $34,000 after buying an additional 27 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly CEO David Ricks said approximately 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July, with Lilly capturing about 70% of those new patients. Foundayo also represents roughly one-third of new oral GLP-1 prescriptions, with its share growing weekly. CNBC Medicare coverage article
• Positive Sentiment: Lilly broke ground on a planned $6.5 billion Houston manufacturing facility that will produce active ingredients for medicines including Foundayo. The project is expected to create more than 600 jobs and strengthen domestic supply capacity. Lilly Houston manufacturing announcement
• Positive Sentiment: Investor Ken Langone said Lilly is becoming one of the largest positions in his portfolio and suggested the stock could eventually reach $2,000. Separately, a major global bank reportedly sees approximately 37% upside after the recent pullback. Ken Langone Lilly outlook
• Neutral Sentiment: Lilly and Dragoneer have indicated interest in Oura’s planned IPO. The investment could provide exposure to consumer health data, but it is not expected to materially affect Lilly’s near-term earnings. Oura IPO article
• Negative Sentiment: Competition remains the principal risk. Viking Therapeutics shares surged after positive obesity-drug data, while Roche also reported encouraging results. The developments raise concerns that Lilly’s current obesity-drug dominance could face stronger competition, pressuring the stock alongside Novo Nordisk. Viking and Roche obesity-drug data

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LLY. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 14th. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. Morgan Stanley reissued an "overweight" rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,305.25.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $5.09 during trading on Tuesday, reaching $1,169.98. 1,111,489 shares of the stock traded hands, compared to its average volume of 3,013,810. The company has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.28, a P/E/G ratio of 1.42 and a beta of 0.50. The business has a fifty day simple moving average of $1,176.50 and a two-hundred day simple moving average of $1,078.33. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 52-week low of $712.05 and a 52-week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same period in the prior year, the firm earned $6.31 EPS. The company's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 36.54 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.